US Patent 4,061,779: scope, claim architecture, and US landscape for anti-inflammatory 4-(6’-methoxy-2’-naphthyl)butan-2-one compositions

US Patent 4,061,779 covers oral pharmaceutical compositions and human methods for anti-inflammatory use of a specific substituted ketone compound, with dose-range limits and a key functional limitation tying anti-inflammatory effect to absence of undesired oestrogenic effect. The claims split into (i) composition claims, (ii) method claims, (iii) administration-form and dose-spec limitations, and (iv) a materials/solid-state definition (melting point), which can matter for enforceability against non-identical crystalline forms or salt-like variants.

What does US 4,061,779 claim, in plain scope terms?

Core compound and use theme

The patent claims pharmaceutical compositions “useful for treating inflammation in humans” comprising an anti-inflammatory effective amount of a compound “of the formula” (shown in the claim set as a substituted ketone) plus a pharmaceutically acceptable carrier, in oral and unit dose formats.

A second set of claims targets rheumatic and arthritic conditions using the same compound family/formula.

Primary claim levers

Across the claim set, the scope is driven by four levers:

Compound identity: the compound “of the formula” appearing in claims 1, 3-4, 5, and 13 (with claim 13 adding a solid-state specification).
Therapeutic function: anti-inflammatory treatment and (in methods) explicit “reducing inflammation” and “without undesired oestrogenic effect.”
Form factor: oral administration; tablet or capsule in dependent claims.
Dose ranges: unit-dose mg ranges, and sub-range tablet/capsule mg ranges.

How are the claims structured and what does each bucket cover?

A. Composition claims (human anti-inflammatory; carriers; oral formats)

Claim 1
A pharmaceutical composition useful for treating inflammation in humans comprising an anti-inflammatory effective amount of the formula compound in combination with a pharmaceutically acceptable carrier.

Claim 2
Claim 1 composition in oral administration form.

B. Composition claims with dose and unit-dose limits

Claim 3
Oral unit-dose composition comprising 20 mg to 1000 mg per unit dose of the formula compound.

Claim 4
Tablet or capsule composition comprising 100 mg to 600 mg of the formula compound.

These dose bands are often the decisive boundary for design-around and for infringement analysis (product labeling, strength per unit, and dosing granularity).

C. Composition claims for rheumatic/arthritic conditions

Claim 5
Composition useful for treatment of rheumatic and arthritic conditions comprising a therapeutically effective amount of the formula compound plus carrier.

Claim 6
Claim 5 composition in oral administration form.

D. Method claims (human dosing; functional estrogenicity limitation)

Claim 7
Method of reducing inflammation in humans by administering to a human an amount of the composition of claim 1 sufficient to produce an anti-inflammatory effect “without an undesired oestrogenic effect.”

This is the most legally distinctive limitation in the method set because it is both functional and safety/pharmacology-conditioned. It can also create evidentiary complexity: a product could technically reduce inflammation while still raising or not raising estrogenicity.

Claim 8
Method of claim 7 where the composition is administered orally.

Claim 9
Method where the composition is unit dose for oral administration with 20 mg to 1000 mg per unit dose.

Claim 10
Method where the unit dose has 100 mg to 600 mg.

E. Method claims for rheumatic/arthritic relief

Claim 11
Method of treating rheumatic and arthritic conditions by administering an amount of the composition of claim 5 sufficient to provide relief.

Claim 12
Claim 11 administered orally.

F. A solid-form limitation

Claim 13
Solid “4-(6’-methoxy-2’-naphthyl)butan-2-one” having a melting point of not less than 78.5°C.

This claim is materially different from the “composition of formula” language. It pins scope to a solid-state property. It can matter when accused products use:

the same chemical but a different crystal form (different melting point),
a mixture or amorphous form (melting behavior differs),
or a form with impurities/solvent leading to a depressed melting point.

What are the exact quantitative boundaries (dose) inside the claim set?

Claim	Context	Dose limitation (compound per unit)	Administration/form
3	Oral unit dose composition	20 mg to 1000 mg	Oral unit dose
4	Tablet or capsule	100 mg to 600 mg	Tablet or capsule
9	Oral method (unit dose)	20 mg to 1000 mg	Oral unit dose method
10	Oral method (unit dose)	100 mg to 600 mg	Tablet/capsule-aligned strength range

Practical infringement implication: If a competitor sells a product with strengths outside the claimed per-unit range, direct infringement under dose-limited claims (3,4,9,10) weakens. Composition claims without explicit mg caps (claim 1 and 2; and claim 5 and 6) can still create risk depending on whether an accused product’s dose is argued to be “anti-inflammatory effective amount” and whether carriers/formulation fall within “pharmaceutically acceptable carrier.”

What is the unique estrogenicity limitation, and why it changes the case?

Claim 7 imposes the condition that the administration produces anti-inflammatory effect “without an undesired oestrogenic effect.”

This does two things for scope:

Functional condition on method infringement. The accused regimen has to be argued to meet the “no undesired estrogenic effect” requirement.
Potential route for design-around via pharmacology. If a candidate formulation changes absorption kinetics or metabolites such that estrogenic activity is altered, the limitation becomes a fact question tied to estrogenicity profiling.

From a landscape standpoint, this limitation also tends to pull in:

pharmacology/biomarker evidence,
in vitro receptor assays or in vivo estrogenicity models,
adverse effect discussions (labeling constraints and data).

What about claim 13: melting point and solid-state coverage?

Claim 13 is a narrower “material claim” rather than a composition-in-use claim. It covers:

specific solid form identity: “Solid 4-(6’-methoxy-2’-naphthyl)butan-2-one”
and solid property: melting point ≥ 78.5°C.

A product can avoid claim 13 if it uses a form with:

melting point below 78.5°C,
a different polymorph,
amorphous material,
or a different hydrate/solvate system.

Even if the active ingredient is chemically identical, the melting point constraint can create a non-infringement pathway if the accused manufacturing results in a different solid form and measured melting point.

How does this patent likely sit in a US patent landscape?

Enforceable territory within the US

This patent’s claim set is focused on:

human use (anti-inflammatory; rheumatic/arthritic treatment),
oral delivery (oral form; tablet/capsule),
dose ranges (20–1000 mg; 100–600 mg),
a specific solid form (m.p. ≥ 78.5°C).

In a US landscape context, that typically places the patent at the “drug product use and formulation” layer rather than the “core chemical synthesis intermediates” layer (no synthetic/process claims are present in the excerpt you provided).

Typical competitor threat vectors

For a competitor contemplating entry or switching:

Same active ingredient, same solid form, same strengths: highest risk. Claims 1-4 and 7-10 align tightly with such launches.
Same active ingredient but different solid form: claim 13 risk may drop; composition/method claims still remain unless the substitution also changes dose form and the argument of “anti-inflammatory effective amount” and “therapeutically effective amount” fails.
Different dosing regimen/strengths: risk reduces for claims with fixed mg ranges (3,4,9,10) but not necessarily for claims without mg caps (1,2,5,6,7,8,11,12).
Different route (not oral): direct claim 2,8,6,12 risk drops, but claim 1 and claim 5 still capture compositions broadly with a carrier, unless “oral administration form” is required in the specific claim being asserted.

Practical design-around map (based on claim text)

Design change	Claims most affected	Likely residual risk
Change oral strength to outside 20–1000 mg per unit	3,9	1,2,7,8,5,6,11,12 remain
Change tablet/capsule strength outside 100–600 mg	4,10	1,2,7,8,5,6,11,12 remain
Use non-matching solid form (m.p. < 78.5°C)	13	Composition/method claims still remain on formulation and dosing
Show anti-inflammatory effect but with estrogenicity considered “undesired”	7	Method scope can still be contested; composition claims remain

What is the scope of the “formula” claims, given the excerpt?

The claims repeatedly reference “a compound of the formula” but the excerpt does not reproduce the complete chemical structure textually beyond the formula placeholders (STR26/27/28/29). That means the legal boundary for “formula compound” depends on the actual structural depiction in the patent document, not simply the partial textual name appearing in claim 13.

Still, claim 13 anchors one specific chemical identity as 4-(6’-methoxy-2’-naphthyl)butan-2-one with a defined melting point threshold. That anchor can be used in landscape mapping to relate the “formula” to the same ketone, at least as far as claim 13 is concerned.

Claim-by-claim infringement targets for a hypothetical generic or reformulation

Below is a claimant-centric view of what an accused product would need to have to fall within each claim:

Claim	What an accused product/regimen must show
1	Contains the formula compound at an amount argued to be anti-inflammatory effective, plus pharmaceutically acceptable carrier
2	Formulated for oral administration
3	Oral unit dose contains 20–1000 mg compound
4	Tablet/capsule contains 100–600 mg compound
5	Intended/used to treat rheumatic/arthritic conditions; compound at therapeutically effective amount
6	Oral form
7	Regimen reduces inflammation without undesired estrogenic effect
8	Oral method
9	Oral unit dose method with 20–1000 mg
10	Oral unit dose method with 100–600 mg
11	Regimen provides relief from rheumatic/arthritic condition
12	Oral
13	Solid 4-(6’-methoxy-2’-naphthyl)butan-2-one with melting point ≥ 78.5°C

Why this patent matters for investment and R&D decisions

This patent’s claim pattern implies a business reality for any development program around the same ketone scaffold: you do not only need “a compound that works,” you also need alignment on:

oral product form and dose strength bands,
human therapeutic framing (inflammation; rheumatic/arthritic conditions),
and, for method claims, estrogenicity profile sufficient to argue “without undesired oestrogenic effect.”

For portfolio strategy, claim 13 can also constrain the formulation/manufacturing route to solid-state properties.

Key Takeaways

US 4,061,779 is centered on oral human anti-inflammatory use of a substituted ketone, with dose-range guardrails in unit-dose and tablet/capsule strengths.
The strongest distinctive limitation is the method requirement that inflammation reduction occurs “without an undesired oestrogenic effect.”
Claim 13 is a solid-state anchor: 4-(6’-methoxy-2’-naphthyl)butan-2-one with melting point ≥ 78.5°C, creating a potential design-around via alternative solid forms.
For market entry planning, the most direct risk clustering sits where products match (i) oral dosing, (ii) strength ranges, and (iii) the solid-state form.

FAQs

Do the composition claims require oral administration?
Claim 1 does not require oral form, but claim 2 does. Similarly, claim 5 does not require oral form, but claim 6 does.
Which claims include the 20 mg to 1000 mg range?
Claims 3 and 9.
Which claims include the 100 mg to 600 mg range?
Claims 4 and 10.
What is the practical significance of the “without undesired oestrogenic effect” language?
It adds a functional pharmacology limitation to the method claim scope and can require estrogenicity-focused evidence tied to the administered regimen.
Does claim 13 overlap with the composition claims?
It overlaps only partially. Claim 13 is a solid-form limitation tied to melting point and a specific named ketone, while composition/method claims are broader around formulation, dosing, and therapeutic use.

References (APA)

[1] US Patent 4,061,779.

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	42550/73	Sep 11, 1973

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	7313674	⤷ Start Trial
Belgium	819794	⤷ Start Trial
Switzerland	599090	⤷ Start Trial
Switzerland	603523	⤷ Start Trial
Switzerland	603524	⤷ Start Trial
Switzerland	603525	⤷ Start Trial
Switzerland	603526	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 4,061,779

Summary for Patent: 4,061,779